Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Company Contact | |
Address: | 2400 Skymark Ave Unit 6 MISSISSAUGA ON L4W 5K5 |
Tel: | 1-647-8724849 |
Website: | https://profoundmedical.com |
IR: | See website |
Key People | ||
Arun Swarup Menawat Chairman of the Board, Chief Executive Officer | Mathieu Burtnyk Senior Vice President - Product Leader | Rashed Dewan Chief Accounting Officer, Vice President - Finance |
Abbey Goodman Chief Commercial Officer, US | Hartmut Warnken Chief Commercial Officer - OUS |
Business Overview |
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases. |
Financial Overview |
For the fiscal year ended 31 December 2023, Profound Medical Corp revenues increased 8% to $7.2M. Net loss increased less than 1% to $28.6M. Revenues reflect United States (Country) segment increase of 51% to $5.1M, Germany segment increase of 3% to $1.8M. Net loss reflects Medical Technology segment loss decrease of 11% to $28.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.38 to -$1.35. |
Employees: | 131 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $232.24M as of Dec 31, 2023 |
Annual revenue (TTM): | $9.91M as of Dec 31, 2023 |
EBITDA (TTM): | -$37.81M as of Dec 31, 2023 |
Net annual income (TTM): | -$39.33M as of Dec 31, 2023 |
Free cash flow (TTM): | -$30.69M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 24,428,899 as of Mar 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |